Aveanna Healthcare Holdings Inc. AVAH R2K

Healthcare · Medical Care Facilities · United States

https://www.aveanna.com

Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers private duty nursing (PDN) services, which include in-home skilled nursing services to medically complex children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and non-clinical care, including support services and personal care services; and in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Market & Price

Market Cap

$1.56B

Current Price

$7.17

High / Low (52W)

$10.27 / $3.74

Beta

1.93

Valuation

Stock P/E

5.93

Industry PE

23.65

Forward P/E

9.61

PEG Ratio

Book Value

$1.11

Price to Book

6.48

P/S

0.62

EV/EBITDA

9.24

Dividend Yield

Profitability & Returns

ROCE

15.19%

ROE

ROA

10.17%

Profit Margin

10.37%

Op Margin

11.18%

EPS (Latest Qtr)

$0.19

EPS (TTM)

$1.21

Balance Sheet & Liquidity

Debt/Equity

6.24

Quick Ratio

1.36

Current Ratio

1.47

Debt

$1.50B

Total Assets

$2.01B

Current Assets

$560.23M

Working Capital

$135.78M

Ownership

Promoter Holding

5.80%

Chg in Prom Hold

-0.01%

FII / Inst Holding

91.84%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$2.87B

Total Revenue (TTM)

$2.52B

EBITDA

$310.06M

Free Cash Flow

$82.58M

Operating Cash Flow

$138.84M

Shares Outstanding

217.76M

Gross Margin

32.76%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

10.82%

Profit 5Y

44.66%

Revenue (YoY)

15.90%

Earnings (YoY)

612.30%

PROS

Compounding revenue at 10.8% over 5 years.
Profit CAGR of 44.7% over 5 years.
Generates positive free cash flow.

CONS

Trading 30.2% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	AVAH Aveanna Healthcare Holdings Inc. R2K	7.17	5.93	$1.56B	-	15.19%	-	10.82%	44.66%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2020	Jun 2020	Sep 2020	Apr 2021	Jul 2021	Oct 2021	Apr 2022	Jul 2022	Oct 2022	Apr 2023	Jul 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Apr 2026
Revenue	355.22M	351.58M	366.00M	417.16M	436.11M	411.28M	450.53M	442.95M	443.01M	466.41M	471.94M	478.01M	490.65M	504.96M	-	-	559.22M	589.55M	621.94M	662.48M	647.91M	647.91M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	375.67M	378.75M	419.12M	449.18M	442.49M	-
Gross Profit	107.54M	106.63M	114.13M	131.68M	146.59M	139.74M	144.83M	145.04M	134.58M	144.47M	155.25M	147.26M	145.85M	158.27M	-	-	183.56M	210.80M	202.82M	213.30M	205.43M	205.43M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	131.65M	127.37M	150.42M	140.77M	132.99M	-
Operating Income	17.87M	-51.96M	12.88M	28.30M	30.29M	18.35M	13.78M	-456.38M	4.79M	17.64M	37.49M	-76.35M	22.87M	37.13M	-	-	51.91M	83.43M	52.41M	72.53M	72.44M	69.33M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	51.78M	87.11M	55.67M	78.04M	80.82M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34.69M	36.00M	35.13M	31.61M	28.19M	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.15M	44.14M	13.42M	39.24M	44.98M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.96M	17.11M	-647.00K	-139.51M	3.32M	-
Net Income	37.64M	-77.55M	-7.40M	5.80M	1.26M	2.09M	25.33M	-473.89M	24.30M	-32.00M	25.60M	-102.39M	-11.17M	13.91M	-	-	5.19M	27.02M	14.06M	178.75M	41.65M	41.65M
Diluted EPS	0.27	-0.55	-0.05	0.04	0.01	0.01	0.14	-2.56	0.13	-0.17	0.13	-0.54	-0.06	0.07	-	-	0.03	0.13	0.06	0.80	0.19	0.19

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2019	Jan 2021	Dec 2021	Jan 2022	Dec 2022	Dec 2023	Dec 2024	Dec 2025	Jan 2026
Revenue	1.38B	1.50B	-	1.68B	1.79B	1.90B	2.02B	2.43B	2.43B
Cost of Revenue	-	-	-	-	1.23B	1.30B	1.39B	1.62B	-
Gross Profit	419.25M	454.51M	-	542.40M	553.23M	595.43M	635.54M	810.48M	810.48M
Operating Expenses	-	-	-	-	520.06M	481.76M	494.26M	550.21M	-
Operating Income	38.95M	-3.49M	-	-36.11M	33.17M	113.67M	141.28M	260.28M	256.46M
EBITDA	-	-	-	-	-525.06M	39.17M	187.38M	269.40M	-
Interest Expense	-	-	-	-	99.94M	148.07M	151.14M	134.23M	-
Pretax Income	-	-	-	-	-663.81M	-139.00M	5.07M	106.95M	-
Tax Provision	-	-	-	-	-1.78M	-4.47M	16.00M	-118.09M	-
Net Income	-76.52M	-57.05M	-	-117.04M	-662.03M	-134.52M	-10.93M	225.03M	225.03M
Diluted EPS	-	-	-0.69	-0.69	-3.57	-0.71	-0.06	-	1.05

Compounded Sales Growth

5 Years:	10.82%
1 Year:	15.90%

Compounded Profit Growth

5 Years:	44.66%
1 Year:	612.30%

Stock Price Performance

1 Year:	+34.52%
6 Months:	-22.32%
3 Months:	-2.58%
1 Month:	+9.47%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2018	Dec 2019	Jan 2021	Dec 2021	Jan 2022	Dec 2022	Dec 2023	Dec 2024	Dec 2025	Jan 2026
Total Assets	-	-	1.84B	-	2.33B	1.71B	1.61B	1.66B	2.01B	2.01B
Current Assets	-	-	-	-	-	269.75M	314.89M	392.67M	560.23M	-
Cash & Equivalents	-	-	137.34M	-	30.49M	19.22M	43.94M	84.29M	193.26M	193.26M
Inventory	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	225.63M	245.81M	277.66M	316.12M	-
Total Liabilities	-	-	1.58B	-	1.70B	1.72B	1.74B	1.79B	1.82B	1.82B
Current Liabilities	-	-	260.41M	-	344.83M	326.50M	354.76M	402.17M	424.46M	424.46M
Long Term Debt	-	-	1.16B	-	1.23B	1.28B	1.28B	1.27B	1.29B	1.29B
Total Debt	-	-	-	-	-	1.50B	1.50B	1.50B	1.51B	-
Total Equity	344.99M	270.19M	265.03M	-	635.82M	-4.17M	-127.44M	-122.09M	195.19M	194.46M
Shares Outstanding	-	-	-	-	-	188.86M	190.73M	193.23M	211.00M	-

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2019	Jan 2021	Dec 2021	Jan 2022	Dec 2022	Dec 2023	Dec 2024	Dec 2025	Jan 2026
Operating Cash Flow	-8.71M	116.62M	-	-11.35M	-48.40M	22.67M	32.64M	125.86M	125.86M
Investing Cash Flow	-17.82M	-193.54M	-	-681.83M	-25.29M	-8.79M	-6.32M	-22.30M	-22.30M
Financing Cash Flow	21.86M	210.94M	-	586.33M	62.42M	10.85M	14.03M	5.41M	5.41M
Capital Expenditure	-16.64M	-15.24M	-	-15.95M	-12.01M	-8.79M	-6.32M	-7.45M	-
Free Cash Flow	-25.35M	101.38M	-	-27.30M	-60.41M	13.88M	26.32M	118.41M	-
Net Change in Cash	-	-	-	-	-11.27M	24.73M	40.35M	108.97M	-

Ratios (Annual)

Figures in %.

Metric	Dec 2019	Jan 2021	Dec 2021	Jan 2022	Dec 2022	Dec 2023	Dec 2024	Dec 2025	Jan 2026
Gross Margin %	30.3%	30.4%	-	32.3%	30.9%	31.4%	31.4%	33.3%	33.3%
Operating Margin %	2.8%	-0.2%	-	-2.2%	1.9%	6.0%	7.0%	10.7%	10.5%
Net Margin %	-5.5%	-3.8%	-	-7.0%	-37.0%	-7.1%	-0.5%	9.2%	9.2%
ROE %	-28.3%	-21.5%	-	-18.4%	15,857.1%	105.6%	9.0%	115.3%	115.7%
ROCE %	-	-0.2%	-	-1.8%	2.4%	9.0%	11.2%	16.4%	16.2%

Shareholding Pattern

Insiders

5.80%

Institutions

91.84%

Public Float

97.49%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Bain Capital Investors Llc	37.47%	81.60M	$585.08M
2	J.H. Whitney Equity Partners VII, LLC	16.64%	36.24M	$259.86M
3	Nut Tree Capital Management, LP	5.93%	12.92M	$92.66M
4	Blackrock Inc.	2.53%	5.50M	$39.44M
5	Summit Partners, L.P.	2.50%	5.45M	$39.09M
6	Vanguard Capital Management LLC	1.83%	3.97M	$28.50M
7	Boston Partners	1.30%	2.82M	$20.25M
8	Nuveen, LLC	1.01%	2.19M	$15.74M
9	Littlejohn & Co LLC	1.01%	2.20M	$15.80M
10	Braidwell LP	1.01%	2.20M	$15.80M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AVAH

No recent headlines available.

AVAH · Healthcare